This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Etoreat

Kowa Company, Ltd.

Drug Names(s): Etodolac-lidocaine patch, MRX-7EAT

Description: Etoreat is a topical patch containing etodolac, a non-steroidal, anti-inflammation drug, and lidocaine.

Deal Structure: Kowa and MEDRx
In March 2011, Kowa and MEDRx announced that the companies have signed a definitive agreement under which Kowa will acquire exclusive sales rights for the United States and Commonwealth of Puerto Rico to sell a topical patch containing etodolac for which Phase III clinical trials in the treatment of acute pain are being conducted by IL Pharma Inc. which is a held subsidiary of MEDRx.Under the terms of the agreement, KOWA or its subsidiaries will market and sell the etodolac patch in the United States and the Commonwealth of Puerto Rico exclusively. MEDRx will receive the upfront, development and sales milestone payments from Kowa and supply the etodolac patch in the United States and Puerto Rico exclusively. And MEDRx is also eligible to receive tiered royalties on the product sales.

Partners: MEDRx Co., Ltd.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug